

October 24, 2022



## Oragenics to Participate in the 2022 BioFlorida Annual Conference

TAMPA, Fla.--(BUSINESS WIRE)-- **Oragenics, Inc. (NYSE American: OGEN)** (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.

Kim Murphy, President and CEO, will be participating on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3 from 2:05 p.m. to 3:05 p.m.

**Panel:** BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases  
**Date:** Thursday, November 3, 2022  
**Time:** 2:05 p.m. Eastern Time  
**Location:** Hyatt Regency Miami

Ms. Murphy will also be participating in BioFlorida’s one-on-one investor and business development meetings. Please contact [LHA Investor Relations](#) to schedule a meeting.

### About Oragenics, Inc.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit [www.oragenics.com](http://www.oragenics.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20221024005965/en/>

### Oragenics, Inc.

Michael Sullivan, Chief Financial Officer

813-286-7900

[msullivan@oragenics.com](mailto:msullivan@oragenics.com)

### LHA Investor Relations

Tirth T. Patel  
212-201-6614  
[tpatel@lhai.com](mailto:tpatel@lhai.com)

Source: Oragenics, Inc.